Pub Date : 2026-01-28DOI: 10.1038/s41408-025-01432-4
Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage
{"title":"Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up","authors":"Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage","doi":"10.1038/s41408-025-01432-4","DOIUrl":"https://doi.org/10.1038/s41408-025-01432-4","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"14 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146089561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-12DOI: 10.1038/s41408-025-01447-x
Huiqin Bian,Naseema Gangat,Na Shen,Jiuxia Pang,David Wald,William Tse,Ayalew Tefferi,Fei Yan,Shujun Liu
{"title":"NFκB/IL-6/JAK2/STAT axis in myelofibrosis is a key vulnerability that is targetable and relevant to JAK2 inhibitor treatment resistance.","authors":"Huiqin Bian,Naseema Gangat,Na Shen,Jiuxia Pang,David Wald,William Tse,Ayalew Tefferi,Fei Yan,Shujun Liu","doi":"10.1038/s41408-025-01447-x","DOIUrl":"https://doi.org/10.1038/s41408-025-01447-x","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"28 1","pages":"13"},"PeriodicalIF":12.8,"publicationDate":"2026-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145955484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-09DOI: 10.1038/s41408-025-01435-1
Hervé Ghesquières,Youenn Drouet,Susan L Slager,Franck Morschhauser,Edith Julia,Sara Galimberti,Dennis Robinson,Melissa C Larson,Quentin Testard,Bruno Tesson,Jean-François Deleuze,Anne Boland,Emilie Thomas,Christine Lasset,Anne J Novak,Luc Xerri,Stefano Luminari,Aurelie Verney,Camille Laurent,Lisa M Rimsza,Thomas M Habermann,Massimo Federico,Brian K Link,Gilles Salles,James R Cerhan
Genome-wide association studies (GWAS) have identified germline genetic variants for follicular lymphoma (FL) susceptibility. We conducted a GWAS of prognosis in FL patients to identify genetic predictors of event-free survival (EFS) as well as failure within the first 24 months after treatment initiation (EFS24) using patients treated with rituximab-based immunochemotherapy from three clinical trials and one prospective observational study (N = 1054). Statistical approaches consisted of a pooled GWAS of the four cohorts and a leave-one-cohort-out (LOCO) strategy to identify robust findings that replicated across the four cohorts. The top SNPs for EFS and EFS24 were marked by rs72625024 at 3q27.3 near FETUB and HRG (P = 9.37 × 10-8) and rs114695031 at 14q32.13 near TCL6 (P = 1.93 × 10-8), respectively. These two loci, which were discovered and validated in all 4 LOCO rounds, map near long-non-coding RNAs with putative tumor suppressor functions. Our results pinpoint potential novel biology and the contribution of host genetics to prognosis in FL.
{"title":"Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy.","authors":"Hervé Ghesquières,Youenn Drouet,Susan L Slager,Franck Morschhauser,Edith Julia,Sara Galimberti,Dennis Robinson,Melissa C Larson,Quentin Testard,Bruno Tesson,Jean-François Deleuze,Anne Boland,Emilie Thomas,Christine Lasset,Anne J Novak,Luc Xerri,Stefano Luminari,Aurelie Verney,Camille Laurent,Lisa M Rimsza,Thomas M Habermann,Massimo Federico,Brian K Link,Gilles Salles,James R Cerhan","doi":"10.1038/s41408-025-01435-1","DOIUrl":"https://doi.org/10.1038/s41408-025-01435-1","url":null,"abstract":"Genome-wide association studies (GWAS) have identified germline genetic variants for follicular lymphoma (FL) susceptibility. We conducted a GWAS of prognosis in FL patients to identify genetic predictors of event-free survival (EFS) as well as failure within the first 24 months after treatment initiation (EFS24) using patients treated with rituximab-based immunochemotherapy from three clinical trials and one prospective observational study (N = 1054). Statistical approaches consisted of a pooled GWAS of the four cohorts and a leave-one-cohort-out (LOCO) strategy to identify robust findings that replicated across the four cohorts. The top SNPs for EFS and EFS24 were marked by rs72625024 at 3q27.3 near FETUB and HRG (P = 9.37 × 10-8) and rs114695031 at 14q32.13 near TCL6 (P = 1.93 × 10-8), respectively. These two loci, which were discovered and validated in all 4 LOCO rounds, map near long-non-coding RNAs with putative tumor suppressor functions. Our results pinpoint potential novel biology and the contribution of host genetics to prognosis in FL.","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"49 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145937816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-08DOI: 10.1038/s41408-025-01434-2
Matthew S Davids, Stephan Stilgenbauer, Constantine S Tam
In the decade since FDA approval of the first-generation Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted agents, as monotherapy or in combination regimens, have decisively replaced chemoimmunotherapy as the standard of care. In national CLL guidelines updated from 2023 through 2025 - including those from France, Germany, and the US - chemoimmunotherapy is considered a treatment option in only exceptional cases, reflecting broad consensus among experts that targeted therapies should be used universally in the management of previously untreated CLL. The primary first-line treatment options for CLL comprise continuous therapies based on the BTK inhibitors ibrutinib, zanubrutinib, or acalabrutinib, or fixed-duration regimens combining the BCL2 inhibitor venetoclax with obinutuzumab or the BTK inhibitors ibrutinib or acalabrutinib (with or without obinutuzumab). Selecting the appropriate targeted therapy requires careful evaluation of a multitude of factors, including molecular disease features (especially del[17p]/TP53 and IGHV mutational status), comorbidities, comedications, and the patient's preferences. Focusing on primary treatment options, we review data from the key controlled trials that support the first-line use of targeted therapies for patients with CLL, consider ongoing trials that may support clinical decision-making in the future, and assess the potential to personalize treatment regimens in CLL based on minimal residual disease status.
{"title":"First-line treatment for CLL in the era of targeted therapy.","authors":"Matthew S Davids, Stephan Stilgenbauer, Constantine S Tam","doi":"10.1038/s41408-025-01434-2","DOIUrl":"10.1038/s41408-025-01434-2","url":null,"abstract":"<p><p>In the decade since FDA approval of the first-generation Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted agents, as monotherapy or in combination regimens, have decisively replaced chemoimmunotherapy as the standard of care. In national CLL guidelines updated from 2023 through 2025 - including those from France, Germany, and the US - chemoimmunotherapy is considered a treatment option in only exceptional cases, reflecting broad consensus among experts that targeted therapies should be used universally in the management of previously untreated CLL. The primary first-line treatment options for CLL comprise continuous therapies based on the BTK inhibitors ibrutinib, zanubrutinib, or acalabrutinib, or fixed-duration regimens combining the BCL2 inhibitor venetoclax with obinutuzumab or the BTK inhibitors ibrutinib or acalabrutinib (with or without obinutuzumab). Selecting the appropriate targeted therapy requires careful evaluation of a multitude of factors, including molecular disease features (especially del[17p]/TP53 and IGHV mutational status), comorbidities, comedications, and the patient's preferences. Focusing on primary treatment options, we review data from the key controlled trials that support the first-line use of targeted therapies for patients with CLL, consider ongoing trials that may support clinical decision-making in the future, and assess the potential to personalize treatment regimens in CLL based on minimal residual disease status.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":" ","pages":"19"},"PeriodicalIF":11.6,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12847715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145931455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-07DOI: 10.1038/s41408-025-01446-y
Domitilla Baccon, Suheil Albert Atallah-Yunes, Paul J Hampel, Lindsey E Roeker, Saad S Kenderian, Eli Muchtar, Neil E Kay, Amber B Koehler, Amy L Behnken, Catherine C Wagner, Patrick B Johnston, Grzegorz S Nowakowski, Thomas M Habermann, Talal Hilal, Mazie Tsang, Jose F Leis, Allison C Rosenthal, Ricardo D Parrondo, Han W Tun, Min Shi, Rebecca L King, Rong He, Sameer A Parikh, Yucai Wang
{"title":"Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience.","authors":"Domitilla Baccon, Suheil Albert Atallah-Yunes, Paul J Hampel, Lindsey E Roeker, Saad S Kenderian, Eli Muchtar, Neil E Kay, Amber B Koehler, Amy L Behnken, Catherine C Wagner, Patrick B Johnston, Grzegorz S Nowakowski, Thomas M Habermann, Talal Hilal, Mazie Tsang, Jose F Leis, Allison C Rosenthal, Ricardo D Parrondo, Han W Tun, Min Shi, Rebecca L King, Rong He, Sameer A Parikh, Yucai Wang","doi":"10.1038/s41408-025-01446-y","DOIUrl":"10.1038/s41408-025-01446-y","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"16 1","pages":"7"},"PeriodicalIF":11.6,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12779626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145916645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-06DOI: 10.1038/s41408-025-01443-1
Toshali Pandey, Bhavesh Mohan Lal, Jawad Alrawabdeh, Marah Alzu’bi, Carolina D. Schinke, Sharmilan Thanendrarajan, Daisy V. Alapat, John D. Shaughnessy, Fenghuang Zhan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi
{"title":"Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma","authors":"Toshali Pandey, Bhavesh Mohan Lal, Jawad Alrawabdeh, Marah Alzu’bi, Carolina D. Schinke, Sharmilan Thanendrarajan, Daisy V. Alapat, John D. Shaughnessy, Fenghuang Zhan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi","doi":"10.1038/s41408-025-01443-1","DOIUrl":"https://doi.org/10.1038/s41408-025-01443-1","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"40 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145902503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-06DOI: 10.1038/s41408-025-01445-z
Sophie Steinhäuser, Thomas Beder, Emely Hübner, Dorothea S. Feuereisel, Jonathan Jebens, Nadine Wolgast, Muhammed Bilal Karaca, Kathrin Richter, Nina Hedemann, Britta Steer, Miriam Denker, Sonja Bendig, Monika Brüggemann, Patricia Silva, Lars Fransecky, Martin Neumann, Friedrich Stölzel, Alina M. Hartmann, Timo Gemoll, Lorenz Bastian, Claudia D. Baldus, Simone Lipinski
{"title":"Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemia","authors":"Sophie Steinhäuser, Thomas Beder, Emely Hübner, Dorothea S. Feuereisel, Jonathan Jebens, Nadine Wolgast, Muhammed Bilal Karaca, Kathrin Richter, Nina Hedemann, Britta Steer, Miriam Denker, Sonja Bendig, Monika Brüggemann, Patricia Silva, Lars Fransecky, Martin Neumann, Friedrich Stölzel, Alina M. Hartmann, Timo Gemoll, Lorenz Bastian, Claudia D. Baldus, Simone Lipinski","doi":"10.1038/s41408-025-01445-z","DOIUrl":"https://doi.org/10.1038/s41408-025-01445-z","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"15 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145902507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-05DOI: 10.1038/s41408-025-01433-3
Robert Meyer, Maria Jimena Rodriguez, Madeline Caduc, Kim Kricheldorf, Matthias Begemann, Florian Kraft, Isabel Spier, Daniela Dey, Nergis Güzel, Kerstin Becker, Julian Baumeister, Marcelo A. S. de Toledo, Susanne Isfort, Ulrich Germing, Stefan Aretz, Tim H. Brümmendorf, Ingo Kurth, Miriam Elbracht, Lino L. Teichmann, Steffen Koschmieder
{"title":"Frequent and clinically relevant germline DNA repair gene variants in young and familial myeloproliferative neoplasms","authors":"Robert Meyer, Maria Jimena Rodriguez, Madeline Caduc, Kim Kricheldorf, Matthias Begemann, Florian Kraft, Isabel Spier, Daniela Dey, Nergis Güzel, Kerstin Becker, Julian Baumeister, Marcelo A. S. de Toledo, Susanne Isfort, Ulrich Germing, Stefan Aretz, Tim H. Brümmendorf, Ingo Kurth, Miriam Elbracht, Lino L. Teichmann, Steffen Koschmieder","doi":"10.1038/s41408-025-01433-3","DOIUrl":"https://doi.org/10.1038/s41408-025-01433-3","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"77 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145902508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：